Two of the funds belonging to the MCI Group, MCI.TechVentures and MCI.BioVentures, recorded very good results in the last year, achieving annual return rates for the year 2011 at the level of, respectively, 28.09% and 28.20%.
âThe investment strategies of the MCI Group funds are based on a selective approach to the sectors in which the companies are operating and to their development stages and they assume active cooperation with the management teams. The appropriateness of such approach is confirmed by the achieved results. In case of the MCI.TechVentures fund, the investment strategy assumes focusing on companies being in the growth stage, active in the market segments having the high growth rate and those segments, the leaders of which achieve the scale synergy and create potential for consolidation of the market,â said Sylwester Janik, manager of MCI.TechVentures, management board member and partner of MCI Management SA.
âThe companies from the medical and biotechnological sector in which MCI.BioVentures has invested fared well during last year and in total they achieved 25% increase of revenues in comparison to year 2010. In May 2011, Genomed SA – a company included in the fundâs portfolio – had its debut at NewConnect, and in December 2011 we performed the first full exit from an investment by selling MedCasco to a strategic investor and achieving an attractive rate of return from the investment. By realizing these actions we commenced a phase of de-investment, which is beneficial to investor since it enables realization of profits. The above actions results in an increase in value of investment certificates of MCI.BioVentrures FIZ by 28.20%, which constitutes one of the best results of investment funds in year 2011. The prospects for the sector for this year seem to be equally interesting, so we intend to continue creating excellent results,â says Grzegorz Gromada, manager of MCI.BioVentures and venture partner of MCI Management SA.